Berlin is trying to stop Washington from persuading a German company to seek a coronavirus vaccine to move its research to the United States, prompting German politicians to insist no country should have a monopoly on any future vaccine.
German government sources told Reuters on Sunday that the U.S. administration was looking into how it could gain access to a potential vaccine being developed by a German firm, CureVac.
Earlier, the Welt am Sonntag German newspaper reported that U.S. President Donald Trump had offered funds to lure CureVac to the United States, and the German government was making counter-offers to tempt it to stay.
There was no comment immediately available from the U.S. embassy in Berlin when contacted by Reuters over the report.
Source: Pew Research Centre
Between Depleting Workforce And Declining Productivity